Alternative Data for Arrowhead Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 89 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 33,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 81 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,409 | Sign up | Sign up | Sign up |
| X Followers | 3,802 | Sign up | Sign up | Sign up |
| X Mentions | 9 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 67 | Sign up | Sign up | Sign up |
| Linkedin Employees | 704 | Sign up | Sign up | Sign up |
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
| Price | $64.52 |
| Target Price | Sign up |
| Volume | 24,090,000 |
| Market Cap | $9.03B |
| Year Range | $14.71 - $73 |
| Dividend Yield | 0% |
| PE Ratio | 40.33 |
| Analyst Rating | 60% buy |
| Industry | Biotechnology |
In the news
 |
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call TranscriptFebruary 5 - SeekingAlpha |
|
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 11 - SeekingAlpha |
 |
Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR)January 10 - Yahoo Entertainment |
|
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches - SlideshowJanuary 7 - SeekingAlpha |
|
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches TranscriptJanuary 5 - SeekingAlpha |
 |
Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity UpdateJanuary 5 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 256M | 0 | 0 | -24M | 0 | -0.180 |
| Q2 '25 | 28M | 6.2M | 22M | -175M | -148M | -1.260 |
| Q1 '25 | 543M | 6.1M | 543M | 370M | 397M | 2.750 |
| Q4 '24 | 2.5M | 5.2M | 2.5M | -173M | -148M | -1.390 |
| Q3 '24 | 24M | 14M | 10M | -171M | -153M | -1.370 |
Insider Transactions View All
| O'Brien Patrick filed to sell 474,908 shares at $68. January 5 '26 |
| O'Brien Patrick filed to sell 484,663 shares at $68. January 5 '26 |
| O'Brien Patrick filed to sell 484,063 shares at $61.1. January 5 '26 |
| O'Brien Patrick filed to sell 483,163 shares at $62.3. January 5 '26 |
| Hamilton James C filed to sell 171,958 shares at $68. January 5 '26 |
Similar companies
Read more about Arrowhead Pharmaceuticals (ARWR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Arrowhead Pharmaceuticals
The Market Cap of Arrowhead Pharmaceuticals is $9.03B.
As of today, Arrowhead Pharmaceuticals' PE (Price to Earnings) ratio is 40.33.
Currently, the price of one share of Arrowhead Pharmaceuticals stock is $64.52.
The ARWR stock price chart above provides a comprehensive visual representation of Arrowhead Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arrowhead Pharmaceuticals shares. Our platform offers an up-to-date ARWR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Arrowhead Pharmaceuticals (ARWR) does not offer dividends to its shareholders. Investors interested in Arrowhead Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Arrowhead Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
